| Uterine Fibroids
Myfembree vs Oriahnn
Side-by-side clinical, coverage, and cost comparison for uterine fibroids.Deep comparison between: Myfembree vs Oriahnn with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOriahnn has a higher rate of injection site reactions vs Myfembree based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Oriahnn but not Myfembree, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Myfembree
Oriahnn
At A Glance
Oral
Daily
GnRH receptor antagonist
Oral
Twice daily
GnRH receptor antagonist
Indications
- Uterine Fibroids
- Menorrhagia
- Endometriosis
- Menorrhagia
- Uterine Fibroids
Dosing
Uterine Fibroids, Menorrhagia One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Endometriosis One tablet orally once daily; start no later than seven days after menses onset; maximum treatment duration 24 months.
Menorrhagia, Uterine Fibroids One elagolix 300 mg/estradiol 1 mg/norethindrone acetate 0.5 mg capsule orally in the morning and one elagolix 300 mg capsule orally in the evening, for up to 24 months.
Contraindications
- High risk of arterial, venous thrombotic, or thromboembolic disorders, including women over 35 who smoke, history of DVT or PE, vascular disease, thrombogenic valvular or rhythm disease, hypercoagulopathy, uncontrolled hypertension, or migraine headaches with aura if over 35
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormone-sensitive malignancy, or increased risk for hormone-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to MYFEMBREE or any of its components
- High risk of arterial, venous thrombotic, or thromboembolic disorders (including women over 35 who smoke and those with history of DVT, pulmonary embolism, vascular disease, thrombogenic cardiac conditions, hypercoagulopathies, uncontrolled hypertension, or migraine with aura over age 35)
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormonally-sensitive malignancies, or increased risk for hormonally-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to ORIAHNN or any of its components
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
Adverse Reactions
Most common (>=3%) Headache, vasomotor symptoms, mood disorders, abnormal uterine bleeding, nausea, toothache, back pain, decreased sexual desire and arousal, arthralgia, fatigue, dizziness, alopecia, libido decreased
Serious Thromboembolic disorders and vascular events, bone loss, suicidal ideation and mood disorders, hepatic impairment and transaminase elevations, elevated blood pressure, uterine fibroid prolapse or expulsion, hypersensitivity reactions
Postmarketing Anaphylactoid reaction, drug eruption, angioedema, urticaria, uterine leiomyoma degeneration
Most common (>=5%) Hot flush, headache, fatigue, metrorrhagia
Serious Thromboembolic and vascular events, bone loss, suicidal ideation and behavior, exacerbation of mood disorders, hepatic transaminase elevations, elevated blood pressure, alopecia, changes in lipid parameters
Pharmacology
GnRH receptor antagonist combination; relugolix competitively binds pituitary GnRH receptors to suppress LH and FSH, reducing ovarian estradiol and progesterone, while co-formulated estradiol mitigates bone loss and norethindrone acetate provides endometrial protection against unopposed estrogen.
GnRH receptor antagonist combination; elagolix competitively binds GnRH receptors in the pituitary gland, suppressing LH and FSH and reducing ovarian estradiol and progesterone, with add-back estradiol/norethindrone acetate to mitigate bone loss and protect the endometrium from unopposed estrogen effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Myfembree
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (6/12) · Qty limit (10/12)
Oriahnn
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Myfembree
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Oriahnn
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Myfembree
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Oriahnn
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$5/momo
Myfembree Copay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MyfembreeView full Myfembree profile
OriahnnView full Oriahnn profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.